Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Programmed Cell Death-Ligand 1 Expression and Clinical Outcomes Among Patients with Resected, Early-Stage Non-Small Cell Lung Cancer: A Real-World Study.
Cheema PK, Syed I, Gwadry-Sridhar F, Rakibuz-Zaman M, Sachdeva R, Pencz A, Zhan L, Hueniken K, Patel D, Balaratnam K, Khan K, Grant B, Sheffield BS, Locke MEO, Moldaver D, Shanahan MK, Liu G, Kuruvilla MS. Cheema PK, et al. Among authors: balaratnam k. Curr Oncol. 2024 Oct 31;31(11):6735-6748. doi: 10.3390/curroncol31110497. Curr Oncol. 2024. PMID: 39590128 Free PMC article.
Treatment patterns and outcomes in KRASG12C-positive advanced NSCLC patients previously treated with immune checkpoint inhibitors: A Canada-wide real-world, multi-center, retrospective cohort study.
Barghout SH, Zhan LJ, Raptis S, Al-Agha F, Esfahanian N, Popovacki A, Kasymjanova G, Proulx-Rocray F, Chan SWS, Richardson M, Brown MC, Patel D, Dean ML, Navani V, Moore E, Carvery L, Yan E, Goldshtein D, Cleary-Gosine J, Gibson AJ, Hubley L, Balaratnam K, Ngo T, Gill A, Black M, Sacher A, Bradbury PA, Shepherd FA, Leighl N, Cheema P, Kuruvilla S, Agulnik J, Banerji S, Juergens R, Blais N, Cheung W, Wheatley-Price P, Liu G, Snow S. Barghout SH, et al. Among authors: balaratnam k. Lung Cancer. 2024 Aug;194:107898. doi: 10.1016/j.lungcan.2024.107898. Epub 2024 Jul 25. Lung Cancer. 2024. PMID: 39074423
Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events.
Middha P, Thummalapalli R, Quandt Z, Balaratnam K, Cardenas E, Falcon CJ; Princess Margaret Lung Group; Gubens MA, Huntsman S, Khan K, Li M, Lovly CM, Patel D, Zhan LJ, Liu G, Aldrich MC, Schoenfeld AJ, Ziv E. Middha P, et al. Among authors: balaratnam k. medRxiv [Preprint]. 2024 Jun 11:2024.06.10.24308518. doi: 10.1101/2024.06.10.24308518. medRxiv. 2024. PMID: 38947092 Free PMC article. Preprint.
Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis.
Middha P, Thummalapalli R, Betti MJ, Yao L, Quandt Z, Balaratnam K, Bejan CA, Cardenas E, Falcon CJ, Faleck DM; Princess Margaret Lung Group; Gubens MA, Huntsman S, Johnson DB, Kachuri L, Khan K, Li M, Lovly CM, Murray MH, Patel D, Werking K, Xu Y, Zhan LJ, Balko JM, Liu G, Aldrich MC, Schoenfeld AJ, Ziv E. Middha P, et al. Among authors: balaratnam k. Nat Commun. 2024 Mar 26;15(1):2568. doi: 10.1038/s41467-023-44512-4. Nat Commun. 2024. PMID: 38531883 Free PMC article.
Presentation and outcomes of KRASG12C mutant non-small cell lung cancer patients with stage IV disease at diagnosis (de novo) versus at recurrence.
Esfahanian N, Chan SWS, Zhan LJ, Brown MC, Khan K, Lee J, Balaratnam K, Yan E, Parker J, Garcia-Pardo M, Barghout SH, Eng L, Bradbury PA, Shepherd FA, Leighl NB, Sacher AG, Snow S, Juergens R, Liu G. Esfahanian N, et al. Among authors: balaratnam k. Cancer Treat Res Commun. 2023;37:100774. doi: 10.1016/j.ctarc.2023.100774. Epub 2023 Nov 4. Cancer Treat Res Commun. 2023. PMID: 37979334 Free article.
Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis.
Middha P, Thummalapalli R, Betti MJ, Yao L, Quandt Z, Balaratnam K, Bejan CA, Cardenas E, Falcon CJ, Faleck DM; Princess Margaret Lung Group; Gubens MA, Huntsman S, Johnson DB, Kachuri L, Khan K, Li M, Lovly CM, Murray MH, Patel D, Werking K, Xu Y, Zhan LJ, Balko JM, Liu G, Aldrich MC, Schoenfeld AJ, Ziv E. Middha P, et al. Among authors: balaratnam k. medRxiv [Preprint]. 2023 Sep 13:2023.05.15.23289680. doi: 10.1101/2023.05.15.23289680. medRxiv. 2023. Update in: Nat Commun. 2024 Mar 26;15(1):2568. doi: 10.1038/s41467-023-44512-4 PMID: 37292751 Free PMC article. Updated. Preprint.
Real-World Treatment Sequencing, Toxicities, Health Utilities, and Survival Outcomes in Patients with Advanced ALK-Rearranged Non-Small-Cell Lung Cancer.
Schmid S, Cheng S, Chotai S, Garcia M, Zhan L, Hueniken K, Balaratnam K, Khan K, Patel D, Grant B, Raptis R, Brown MC, Xu W, Moriarty P, Shepherd FA, Sacher AG, Leighl NB, Bradbury PA, Liu G. Schmid S, et al. Among authors: balaratnam k. Clin Lung Cancer. 2023 Jan;24(1):40-50. doi: 10.1016/j.cllc.2022.09.007. Epub 2022 Sep 24. Clin Lung Cancer. 2023. PMID: 36270866
EGFR mutation prevalence, real-world treatment patterns, and outcomes among patients with resected, early-stage, non-small cell lung cancer in Canada.
Sara Kuruvilla M, Liu G, Syed I, Gwadry-Sridhar F, Sheffield BS, Sachdeva R, Pencz A, Zhan L, Hueniken K, Patel D, Balaratnam K, Khan K, Grant B, Noy S, Singh K, Liu L, Rakibuz-Zaman M, Moldaver D, Kate Shanahan M, Cheema PK. Sara Kuruvilla M, et al. Among authors: balaratnam k. Lung Cancer. 2022 Nov;173:58-66. doi: 10.1016/j.lungcan.2022.08.023. Epub 2022 Sep 12. Lung Cancer. 2022. PMID: 36152478
Treatment patterns and outcomes in early-stage ALK-rearranged non-small cell lung cancer.
Schmid S, Garcia M, Cheng S, Zhan L, Chotai S, Balaratnam K, Khan K, Patel D, Catherine Brown M, Sachdeva R, Xu W, Shepherd FA, Sacher A, Leighl NB, Bradbury P, Moriarty P, Sara Kuruvilla M, Liu G. Schmid S, et al. Among authors: balaratnam k. Lung Cancer. 2022 Apr;166:58-62. doi: 10.1016/j.lungcan.2022.01.020. Epub 2022 Feb 3. Lung Cancer. 2022. PMID: 35183992
13 results